Last reviewed · How we verify
Forane (ISOFLURANE)
Isoflurane (Forane), marketed by Baxter, is a general anesthetic agent currently holding a significant position in the anesthesia market, despite facing competition from multiple off-patent alternatives. Its key strength lies in its well-established mechanism of action through the activation of the 5-hydroxytryptamine receptor 2B, contributing to its reliable induction and maintenance of anesthesia. The primary risk to Isoflurane's market position is the availability of several generic competitors within the same class, including halothane, enflurane, desflurane, and sevoflurane, all of which are off-patent and widely available.
At a glance
| Generic name | ISOFLURANE |
|---|---|
| Sponsor | Baxter |
| Drug class | General Anesthetic [EPC] |
| Target | 5-hydroxytryptamine receptor 2B |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1979 |
Approved indications
- General anesthesia
Common side effects
- Delirium
- Agitation
- Cough
- Breath holding
- Laryngospasm
- Nausea
- Vomiting
- Chills/shivering
- Movement
- Ventricular arrhythmia
- Nodal arrhythmia
- Atrial arrhythmia
Drug interactions
- amfepramone
- amfetamine
- benzphetamine
- dexamfetamine
- dexmethylphenidate
- dobutamine
- dopamine
- ephedrine
- epinephrine
- formoterol
- indacaterol
- isometheptene
Key clinical trials
- Total Intravenous and Balanced Anesthesia in Diabetic Patients Undergoing Video-Assisted Thoracoscopy (PHASE4)
- Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU2) (PHASE3)
- Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU1) (PHASE3)
- Comparison of Two Sedative Agents in Terms of Controlled Hypotension (NA)
- Expanded Access for Inhaled Isoflurane Delivered Via the Sedaconda ACD-S for Sedation of Difficult-to-Sedate Adult Mechanically Ventilated Intensive Care Unit Patients
- Desflurane Versus Isoflurane for Speeding Postanesthetic Recovery and Hospital Discharge (NA)
- Inhaled Sedation in Critically Ill Patients (PHASE4)
- Reduction of Muscle Catabolism Through Brain Activation in Burn Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Forane CI brief — competitive landscape report
- Forane updates RSS · CI watch RSS
- Baxter portfolio CI